SEC Form 4 · accession 0001193125-26-390624
BridgeBio Oncology Therapeutics, Inc. · BBOT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Cobo
Officer — Principal Accounting Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001869105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 10, 2026 | A | 9,038 | $0.00 | A | 14,344 | D | |
| Common StockF2 | Sep 10, 2026 | F | 203 | $5.52 | D | 14,141 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $5.52 | Sep 10, 2026 | A | 43,700 | A | — | Sep 9, 2036 | Common Stock | 43,700 | 43,700 | D |
Explanation of responses
- F1Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.
- F2Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs.
- F31/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.